Screener
Arbutus Biopharma Corporation ABUS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 7:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001447028-26-000021
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net income (loss) | $169,695 | $(24,526) |
| Net income (loss) per common share | ||
| Basic | $0.88 | $(0.13) |
| Diluted | $0.87 | $(0.13) |
| Weighted average number of common shares | ||
| Basic | 193,768,641 | 190,707,085 |
| Diluted | 195,214,067 | 190,707,085 |
| Comprehensive income (loss) |
ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)
FAQ
- What is Arbutus Biopharma Corporation's EPS (diluted)?
- Arbutus Biopharma Corporation (ABUS) reported EPS (diluted) of $0.87 in Q1 2026.
- How has Arbutus Biopharma Corporation's EPS (diluted) changed year-over-year?
- Arbutus Biopharma Corporation's EPS (diluted) increased by 769.2% year-over-year, from -$0.13 to $0.87.
- What is the long-term trend for Arbutus Biopharma Corporation's EPS (diluted)?
- Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's EPS (diluted) has grown at a -32.7% compound annual growth rate (CAGR), from -$0.83 to -$0.17.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Arbutus Biopharma Corporation's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude